Bud & Mary’s honest formulation and production process are built on a solid foundation that meets all high quality standards and GMP (Good Manufacturing Practices) requirements. We understand that a reputable formulation and the efficacy and safety of unfinished products are of the utmost importance.
Our core values guide every decision we make at Bud & Mary’s. From seed to your home, our products are made with the perfect balance of expertise and care, resulting in cannabis products you can be proud to consume.
Bud & Mary’s is the first to receive a Cannabis Research License in the United States for clinical trials.
Bud & Mary’s is the first pharmaceutical-type cannabis company to obtain a GMP and GAP (Good Agricultural Practices) certification in the United States.
Hypothesis: Proper dosing of cannabis medicine will lead to symptomatic improvements in dementia patients.
Our expertise and innovative testing has allowed us to conduct a clinical trial with a 30 patient randomized and placebo-controlled pilot study to research the symptomatic improvements proper dosing of cannabis has in dementia patients.
We’ve teamed up with industry experts, including: a neurologist MD, a neuro-inflammatory blood biomarker analysis company, and a brain scan company.
This study is the first randomized placebo-controlled clinical trial to use and dispense purposefully formulated cannabis-derived medicines.
Bud & Mary’s conducts this research in effort to correlate symptomatic improvements with psychological benefits.
Alzheimer’s Disease is the most common form of Dementia and is the 6th leading cause of death in the U.S. There is no known cure for dementia and current support therapies are of limited benefit.
Symptoms of Alzheimer's Disease include: memory loss, personality changes, behavioral problems, mood changes, difficulty solving problems and performing tasks, and sleep disturbances.
Bud & Mary’s is a fully integrated cannabis company with a pharmaceutical approach to cannabis.
